Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine ...
The Kathmandu Post on MSN
Air pollution clouds health, tourism, and economy in Nepal
Kathmandu, Jan. 23 -- Pokhara, Nepal's tourism capital, was shrouded in a thick haze during the peak tourist season in 2024, dimming its iconic mountain vistas and disrupting air travel. Scores of ...
Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025--In ...
Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with ...
The American Lung Association is ‘deeply concerned’ about recent changes to the childhood immunization schedule, including ...
The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...
MACH Engineering reports that industrial air pollution harms economies by increasing healthcare costs and reducing ...
Effective Sjögren’s management demands a strict separation between symptomatic relief for sicca and immunosuppression for ...
Laughing Water Capital reported a 3.9% annual return, emphasizing fundamental growth in core holdings despite a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback